# PARADIGM (NCT02394795)

> Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC

No report yet. It can be ordered.

- Drugs tested: panitumumab
- Indication: first-line RAS wild-type metastatic colorectal cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02394795
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Takeda
- Conditions: Colorectal Cancer
- Interventions: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab; oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
- Enrollment: 823
- Primary outcome: OS in Participants With Left-sided Tumors
- Primary outcome: Overall Survival (OS) in All Participants

## Indexed commentary on PARADIGM so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=paradigm-nct02394795